COVID-19 Update: India restricting API exports; blood tests coming to the U.S. soon

In response to the COVID-19 outbreak, “India has restricted the export of 26 active pharmaceutical ingredients which represents about 10% of their export capacity,” FDA Commissioner Stephen Hahn said Tuesday. Testifying to the Senate Health, Education, Labor and Pensions Committee, Hahn said FDA is “working very closely to look at that list to assess how that will affect the medical supply chain.”

Hahn did not identify the APIs covered by India’s export controls. He said he did not know if the APIs are used in drugs that are being investigated as potential COVID-19 therapies...